priority countermeasure
Defined in 2 places across 2 titles of the United States Code.
For purposes of this section, the term “priority countermeasure” means a drug, biological product, device, vaccine, vaccine adjuvant, antiviral, or diagnostic test that the Secretary determines to be—
(A) a priority to treat, identify, or prevent infection by a biological agent or toxin listed pursuant to section 262a(a)(1) of this title, or harm from any other agent that may cause a public health emergency; or
(B) a priority to diagnose conditions that may result in adverse health consequences or death and may be caused by the administering of a drug, biological product, device, vaccine, vaccine adjuvant, antiviral, or diagnostic test that is a priority under subparagraph (A).
Not later than 180 days after November 13, 2000, the Comptroller General shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Commerce and the Committee on Appropriations of the House of Representatives a report that describes—
Source
- 2002–200442 U.S.C. § 247DThe Public Health and Welfare · Public health countermeasures to a bioterrorist attack · for purposes of this section
For purposes of this section, the term “priority countermeasure” means a drug, biological product, device, vaccine, vaccine adjuvant, antiviral, or diagnostic test that the Secretary determines to be—
(A) a priority to treat, identify, or prevent infection by a biological agent or toxin listed pursuant to section 262a(a)(1) of this title, or harm from any other agent that may cause a public health emergency; or
(B) a priority to treat, identify, or prevent conditions that may result in adverse health consequences or death and may be caused by the administering of a drug, biological product, device, vaccine, vaccine adjuvant, antiviral, or diagnostic test that is a priority under subparagraph (A).
Source
- 2006–present42 U.S.C. § 247DThe Public Health and Welfare · Public health countermeasures to a bioterrorist attack · for purposes of this section
For purposes of this section, the term “priority countermeasure” means a drug, biological product, device, vaccine, vaccine adjuvant, antiviral, or diagnostic test that the Secretary determines to be—
(A) a priority to treat, identify, or prevent infection by a biological agent or toxin listed pursuant to section 262a(a)(1) of this title, or harm from any other agent that may cause a public health emergency; or
(B) a priority to treat, identify, or prevent conditions that may result in adverse health consequences or death and may be caused by the administering of a drug, biological product, device, vaccine, vaccine adjuvant, antiviral, or diagnostic test that is a priority under subparagraph (A).
Not later than 180 days after November 13, 2000, the Comptroller General shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Commerce and the Committee on Appropriations of the House of Representatives a report that describes—
Source
- 2004–200642 U.S.C. § 247DThe Public Health and Welfare · Public health countermeasures to a bioterrorist attack · for purposes of this section
The term “priority countermeasure” has the meaning given such term in section 247d–6(h)(4) 1 of title 42.
Source
- 2013–present21 U.S.C. § 356Food and Drugs · Accelerated approval of priority countermeasures · for purposes of this title
The term “priority countermeasure” has the meaning given such term in section 247d–6(h)(4) of title 42.
Source
- 2002–201321 U.S.C. § 356Food and Drugs · Accelerated approval of priority countermeasures · for purposes of this title